Quick Overview: Interview with Christopher J. Moreau, CEO of Interview with Christopher Moreau, CEO of

Algernon Pharmaceutical S Preclinical Study - Detailed Overview & Context

Interview with Christopher J. Moreau, CEO of Interview with Christopher Moreau, CEO of

Photo Gallery

Algernon Pharmaceutical’s preclinical study of DMT for stroke confirms growth of Neurons by 40%
Algernon Pharmaceuticals DMT Stroke Clinical Program
Algernon Pharmaceuticals Update - IPF/Chronic Cough Studies
Market One Minute - Algernon Pharmaceuticals
Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient
Algernon Pharmaceuticals gains approval for Phase 1 clinical study of DMT for treatment of stroke
Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study
Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study
Algernon Pharmaceuticals Ifenprodil Chronic Cough Study receives positive feedback from U.S. FDA
Algernon Pharmaceuticals subsidiary completes first dosing in Phase 1 clinical study of DMT
Algernon Pharmaceuticals releases details of Phase 2b Chronic Cough Study of Ifenprodil
Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil.
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored